Novo Nordisk (NVO) Partners With Indian Health-Tech Startup

​Novo Nordisk A/S (NYSE:NVO) is one of the Cheap NYSE Stocks to Buy Now. On December 5, Reuters reported that Novo Nordisk A/S (NYSE:NVO) partnered with Indian health-tech startup Healthify to offer nutrition, health, and lifestyle coaching. The deal marks Healthify’s first partnership with a drug maker and aims to partner with more weight loss drugmakers. Under this partnership, Healthify has launched a new patient support program where it offers coaching services to users prescribed Novo’s weight-loss therapies. ​On the other hand, Wall Street has a mixed opinion on the stock due to a 47.86% decrease in share price year-to-date. On December 4, Kerry Holford from Berenberg Bank reiterated a Buy rating on the stock with a $62 price target. However, earlier on December 3, Thibault Boutherin from Morgan Stanley lowered the firm’s price target on Novo Nordisk A/S (NYSE:NVO) from $43 to $42, while maintaining a Sell rating on the stock. ​Boutherin of Morgan Stanley noted they find the European Union pharmaceutical sector set up to stay neutral in 2026. He sees that while the fundamentals are intact and valuations are cheaper compared to historic values, the setup is offset by better EPS growth elsewhere in Europe. ​​​Novo Nordisk A/S (NYSE:NVO) is a global healthcare company focused mainly on diabetes and obesity care. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.